Indian biopharma company Biocon reported third-quarter revenue on Thursday that fell about 3% when compared with the year-earlier period, which included revenue from its domestic branded formulation ...

Biocon in its Environmental, Social and Governance (ESG) scores as assessed by S&P Global’s Corporate Sustainability Assessment (CSA) for 2024 has achieved an improvement to 69 in 2024, up 6 points ...

This app uses Apple Intelligence to generate custom images on your device. You can choose from a list of suggested prompts, or you can enter your own description of an image and your iPhone will ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Purpose: The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, drug interactions, and role in therapy of vildagliptin for the treatment of type 2 diabetes mellitus were reviewed.

Biocon Ltd share price was down by -4.64% from the previous closing price of ₹388.25. Who are peers of Biocon Ltd? The peers of Biocon Ltd are Sun Pharmaceuticals Industries Ltd, Divis ...

Biocon Ltd. key Products/Revenue Segments include Bio Pharmaceuticals, Other Operating Revenue, Waste and Sale of services for the year ending 31-Mar-2024.For the quarter ended 30-09-2024, the company ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Am J Health Syst Pharm. 2007;64(12):1265-1273.

SBI Multi Asset Allocation Fund (G) 15.92 4,16,589 0.23 SBI Multi Asset Allocation Fund (IDCW-M) 15.92 4,16,589 0.23 SBI Multi Asset Allocation Fund (IDCW-Q) 15.92 4 ...

Biocon Ltd. is a Public Limited Listed company incorporated on 29/11/1978 and has its registered office in the State of Karnataka, India. Company's Corporate Identification Number(CIN) is ...